Skip to main content

Catalyst Calendar

Scope

Wed, Sep 30, 2026

1 updates
CNTB
7:00 AM

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85% (p=0.030) – – Rademikibart significantly reduced the rate

Trial Results • Phase 2Topline results Wed, Sep 30, 2026connectbiopharm.com

Tue, Sep 15, 2026

1 updates
CNTB
7:00 AM

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute

Trial Results • Phase 2Topline data release Tue, Sep 15, 2026connectbiopharm.com

Thu, Sep 3, 2026

1 updates

Wed, Aug 12, 2026

1 updates
CNTB
4:05 PM

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO,

Enrollment • Phase 2Enrollment milestone Tue, Jun 30, 2026connectbiopharm.com